Public Meeting Announced for Medicare Clinical Lab Test Payment Decisions

You might care about this because this notice from the Centers for Medicare & Medicaid Services (CMS) announces a public meeting for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests. This meeting will take place virtually on September 15 and 16, 2026. The main goal is to get advice on how Medicare should pay for certain clinical diagnostic laboratory tests, or CDLTs. Specifically, these are tests for which CMS did not receive enough information from private insurers to set payment rates using the usual method. When CMS lacks this data, it needs to decide whether to "crosswalk" (match the test to an existing similar test) or "gapfill" (create a new payment rate based on other data) to determine how much Medicare will pay. The public will have a chance to present their recommendations, including supporting data, on these payment methods. After hearing from the public, the advisory panel will give its own recommendations to the Secretary of Health and Human Services and the Administrator of CMS. This process helps ensure transparency and fairness in how new or under-reported lab tests are priced under Medicare. The deadlines for registration and submitting presentations are August 21, 2026. What is particularly interesting about this notice is the focus on transparency and public involvement in setting Medicare payment rates. Medicare usually pays for clinical lab tests based on the average rates paid by private insurers. However, for some tests, this data is not available. This meeting is a direct invitation for the public, including experts, labs, and other interested parties, to directly influence how these specific tests are paid for. This is not just a formality. The advisory panel seriously considers these public recommendations before making their own suggestions to CMS. This shows a commitment to an open process, especially when the standard data-driven approach cannot be used. It also highlights the ongoing challenge of pricing new medical technologies and ensuring fair reimbursement while managing healthcare costs. The decision to crosswalk or gapfill can have a big impact on a lab's ability to offer certain tests and on patient access to those services. The notice also points out that Congress has repeatedly delayed reporting periods, indicating the complexities and debates surrounding these payment structures. Anyone involved in clinical diagnostic laboratory testing would be very interested in this document. This includes laboratory owners, managers, and staff, especially those who develop or perform tests for Medicare patients. Companies that create or sell diagnostic test kits and equipment would also find this relevant, as payment rates directly affect market viability. Healthcare providers, such as doctors and hospitals, who order these tests for their patients should also pay attention, as payment policies can influence test availability and costs. Policy researchers, health economists, and legal professionals specializing in healthcare or Medicare regulations would also find the notice important for understanding payment methodologies and regulatory processes. Finally, patient advocacy groups and patients themselves might be interested, as payment decisions can affect access to specific diagnostic tests that are crucial for their health and treatment. The process outlined here directly impacts the business side of lab testing and the medical care patients receive.